Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Shattuck Labs (NASDAQ: STTK), a biotechnology company focused on developing novel therapeutics targeting TNF superfamily receptors for inflammatory and immune-related diseases, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.

The company's CEO, Taylor Schreiber, M.D., Ph.D., will deliver a presentation on April 9, 2025, at 3:00 PM EDT and participate in one-on-one meetings during the conference, which runs from April 7-10, 2025. A live webcast of the presentation will be accessible through the company's website, with a replay available for up to 30 days afterward.

AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present at and participate in one-on-one meetings at the 24^th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025.

Conference Details
Format: Presentation and one-on-one meetings
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: April 9, 2025
Time: 3:00 PM EDT
Webcast link: HERE

A live webcast of the 24^th Annual Needham Virtual Healthcare Conference presentation will be available on the Events and Presentations section of the Company’s website. A replay of the webcast will be archived for up to 30 days following the presentation date.

About SL-325
SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck’s preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies, and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. SL-325 has completed a GLP toxicology study in non-human primates, with an IND filing expected in the third quarter of 2025.

About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com 

FAQ

When is Shattuck Labs (STTK) presenting at the 2025 Needham Healthcare Conference?

Shattuck Labs will present on April 9, 2025, at 3:00 PM EDT during the 24th Annual Needham Virtual Healthcare Conference.

How long will STTK's Needham Conference presentation replay be available?

The webcast replay will be archived and available for up to 30 days following the presentation date.

What therapeutic areas does Shattuck Labs (STTK) focus on?

Shattuck Labs focuses on developing novel therapeutics targeting TNF superfamily receptors for inflammatory and immune-related diseases.

Who will represent Shattuck Labs (STTK) at the 2025 Needham Healthcare Conference?

Dr. Taylor Schreiber, Chief Executive Officer of Shattuck Labs, will represent the company at the conference.